Abstract
Reactivation of p53 via MDM2 inhibition.
Highlights
At diagnosis, 498% of neuroblastoma are p53 wild-type with intact downstream apoptotic machinery.[1]
Initial efforts to optimize the Nutlin compounds led to the first investigational MDM2 inhibitor, RG7112.6 Preclinical evaluation of RG7112 demonstrated robust activation of the p53 pathway with a potent antitumor effect in vitro and in vivo.[8,9]
Hai et al tested the efficacy of RG7388 in several cell lines of non-small cell lung cancer.[12]. They confirmed that RG7388 led to p53-dependent apoptosis of cancer cells, and in vivo, RG7388 significantly inhibited subcutaneous tumor xenografts from p53 wild-type cells but not tumors derived from p53 mutant cells
Summary
498% of neuroblastoma are p53 wild-type with intact downstream apoptotic machinery.[1].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
